{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:49Z","timestamp":1787240569952,"version":"build-2736575974"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Non-small cell lung cancer is the leading cause of death globally, affecting both men and women. Emerging evidence has highlighted the apparent role of gut microbiota in reshaping the lung microbial community. Notably, imbalances in the gut microbiome disrupt lung physiology, which increases an individual\u2019s susceptibility to lung diseases. The homing of gut residents to pulmonary sites prompts tumorigenic processes by altering microbial synergism that metabolically reprograms immune effectors to complement tumor growth. Nevertheless, the additive effect of microbiomes induces immune-responsive mechanisms that excessively induce IL-6 and IL-17 at the inflamed site. Consequently, perturbations in cytokine pool boost inflammatory responses toward a pro-tumor effect, implying cytokine duality and the role of these interleukins in regulating gut-lung crosstalk. Inflammation is a natural host defense mechanism activated against foreign stimulants to mount an immune response. At later stages, the inductive effect of IL-6\/17 triggers inflammasome assembly where their accelerated response induces lung epithelial damage, leading to cellular transformation. This implies that the unexplored interconnections between microbiomes and interleukin biology influence immune dynamics that regulate the processes of neoplastic transformation. Here, in this comprehensive review, we comment on the gut-lung crosstalk along with the role of resident microbes in generating immunological responses. Besides, we discuss the IL-6\/17-mediated activation of the inflammasome in attuning tumoral immunity. These dictate the potential of microbiotal lifeforms in generating inflammatory responses, which can therefore serve as potential diagnostic markers in NSCLC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1649517","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T05:11:36Z","timestamp":1764047496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual signaling cascade regulating gut-lung axis in Interleukin-6\/Interleukin-17 for NSCLC immuno pathogenesis"],"prefix":"10.3389","volume":"16","author":[{"given":"Riya","family":"Khilwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailza","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00284-022-02877-7","article-title":"Association of gut microbiota with inflammatory bowel disease and COVID-19 severity: A possible outcome of the altered immune response","volume":"79","author":"Kaushal","year":"2022","journal-title":"Curr Microbiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00009","article-title":"The gut-lung axis in health and respiratory diseases: A place for inter-organ and inter-kingdom crosstalks","volume":"10","author":"Enaud","year":"2020","journal-title":"Front Cell infection Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1038\/s41467-019-13036-1","article-title":"Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis","volume":"10","author":"Johnson","year":"2019","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113810","article-title":"Gut microbiota: A new insight into lung diseases","volume":"155","author":"Ma","year":"2022","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00594-2","article-title":"Bacteria in cancer initiation, promotion and progression","volume":"23","author":"El Tekle","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-023-01722-y","article-title":"Lung microbiome: new insights into the pathogenesis of respiratory diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal transduction targeted Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720842","article-title":"The role of gut microbiota in lung cancer: from carcinogenesis to immunotherapy","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/oxfimm\/iqae008","article-title":"The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections","volume":"5","author":"Sey","year":"2024","journal-title":"Oxford Open Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41698-020-00138-z","article-title":"Microbiome dysbiosis in lung cancer: from composition to therapy","volume":"4","author":"Liu","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12079-022-00695-x","article-title":"Role of interleukin-6-mediated inflammation in the pathogenesis of inflammatory bowel disease: focus on the available therapeutic approaches and gut microbiome","volume":"17","author":"Shahini","year":"2023","journal-title":"J Cell Commun Signal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1624803","article-title":"Gut-lung axis, probiotics, and prebiotics: insights on dysbiosis, mechanism, and prevention of lung cancer","volume":"12","author":"Deepika","year":"2025","journal-title":"Front Nutr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2276314","article-title":"Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment","volume":"15","author":"Zhou","year":"2023","journal-title":"Gut Microbes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00810-1","article-title":"Modulation of the gut microbiome to enhance immunotherapy response in metastatic melanoma patients: A clinical review","volume":"12","author":"Najmi","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S520098","article-title":"Distinct lung adenocarcinoma-associated microbiota are associated with inflammatory immune landscapes and tumor cell proliferation via LCIIAR-ISG15 regulatory networks","volume":"17","author":"Liu","year":"2025","journal-title":"Cancer Manage Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1397989","article-title":"Unveiling microbial dynamics in lung adenocarcinoma and adjacent nontumor tissues: insights from nicotine exposure and diverse clinical stages via nanopore sequencing technology","volume":"14","author":"Yang","year":"2024","journal-title":"Front Cell infection Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1559211","article-title":"Clinical characteristics and risk factors of late-stage lung adenocarcinoma patients with bacterial pulmonary infection and its relationship with cellular immune function","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43168-023-00178-6","article-title":"Prevalence and pattern of isolated fungi from bronchoalveolar lavage among patients with lung cancer: a prospective cross-sectional study","volume":"17","author":"El-Badrawy","year":"2023","journal-title":"Egyptian J Bronchology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12916-023-03095-z","article-title":"Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.chom.2013.12.010","article-title":"Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE2","volume":"15","author":"Kim","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00112","article-title":"Dysbiosis of the gut microbiome in lung cancer","volume":"9","author":"Zhuang","year":"2019","journal-title":"Front Cell infection Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12967-020-02231-0","article-title":"Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment","volume":"18","author":"Botticelli","year":"2020","journal-title":"J Trans Med"},{"key":"B23","article-title":"Alterations of fecal bacterial communities in patients with lung cancer","volume":"10","author":"Zhang","year":"2018","journal-title":"Am J Trans Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ biofilms microbiomes"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0051","article-title":"Association of probiotic clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer","volume":"8","author":"Tomita","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13059-016-1021-1","article-title":"Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features","volume":"17","author":"Yu","year":"2016","journal-title":"Genome Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/2049-2618-1-19","article-title":"Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation","volume":"1","author":"Segal","year":"2013","journal-title":"Microbiome"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03644-0","article-title":"Role of lung and gut microbiota on lung cancer pathogenesis","volume":"147","author":"Zhao","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e44897","DOI":"10.1097\/MD.0000000000044897","article-title":"Gut microbiota influences lung cancer risk through circulating cytokines-Insights from a Mendelian randomization study","volume":"104","author":"Shen","year":"2025","journal-title":"Medicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1589843","article-title":"Lung microbiome alterations correlate with immune imbalance in non-small cell lung cancer","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-393","article-title":"Microbiota modulate immune repertories in lung adenocarcinoma via microbiota-immunity interactive network","volume":"13","author":"Liang","year":"2024","journal-title":"Trans Lung Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-025-01103-3","article-title":"The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment","volume":"48","author":"Yan","year":"2025","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2024.12.006","article-title":"Role of the microbiome in regulation of the immune system","volume":"74","author":"Kim","year":"2025","journal-title":"Allergology Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","article-title":"Interaction between microbiota and immunity in health and disease","volume":"30","author":"Zheng","year":"2020","journal-title":"Cell Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.trecan.2019.12.007","article-title":"The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy","volume":"6","author":"Ram\u00edrez-Labrada","year":"2020","journal-title":"Trends Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20471","article-title":"Screening of plasma IL-6 and IL-17 in Bangladeshi lung cancer patients","volume":"9","author":"Shill","year":"2023","journal-title":"Heliyon"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e70670","DOI":"10.1002\/cam4.70670","article-title":"Tumor-associated macrophages: key players in the non-small cell lung cancer tumor microenvironment","volume":"14","author":"Lv","year":"2025","journal-title":"Cancer Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5035371","article-title":"Desired turbulence? Gut-lung axis, immunity, and lung cancer","volume":"2017","author":"Bingula","year":"2017","journal-title":"J Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.2RI0815-354RR","article-title":"New development in studies of formyl-peptide receptors: critical roles in host defense","volume":"99","author":"Li","year":"2016","journal-title":"J leukocyte Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31537","article-title":"A cytokine-mediated link between innate immunity, inflammation, and cancer","volume":"117","author":"Lin","year":"2007","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2015","article-title":"A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses","volume":"15","author":"Wu","year":"2009","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000511556","article-title":"Microbiome: A supportive or a leading actor in lung cancer","volume":"88","author":"Martins","year":"2021","journal-title":"Pathobiology: J immunopathology Mol Cell Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.35980","article-title":"Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer","volume":"15","author":"Liu","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/frmbi.2025.1606551","article-title":"The microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes","volume":"4","author":"Bailey","year":"2025","journal-title":"Front Microbiomes"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8494079","article-title":"The role of interleukin-17 in lung cancer","volume":"2016","author":"Wu","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08928-y","article-title":"The airway microbiome-IL-17 axis: a critical regulator of chronic inflammatory disease","volume":"64","author":"Mannion","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114483","article-title":"T helper 17 (Th17) cell responses to the gut microbiota in human diseases","volume":"161","author":"Sun","year":"2023","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.51362","article-title":"Biological characteristics of IL-6 and related intestinal diseases","volume":"17","author":"Guo","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114452","article-title":"Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma","volume":"161","author":"Alam","year":"2023","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-023-10596-2","article-title":"Impact of IL-6 and IL-1\u03b2 Gene variants on non-small-cell lung cancer risk in Egyptian patients","volume":"62","author":"Metwally","year":"2024","journal-title":"Biochem Genet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3042","article-title":"Interleukin-6 prevents the initiation but enhances the progression of lung cancer","volume":"75","author":"Qu","year":"2015","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.1038\/s41467-024-51831-7","article-title":"Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer","volume":"15","author":"Hung","year":"2024","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104284","article-title":"Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets","volume":"196","author":"Huang","year":"2024","journal-title":"Crit Rev oncology\/hematology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946832","article-title":"Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis","volume":"13","author":"Wen","year":"2022","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00724-14","article-title":"Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function","volume":"88","author":"Hou","year":"2014","journal-title":"J Virol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.4c00412","article-title":"Leveraging evolutionary immunology in interleukin-6 and interleukin-17 signaling for lung cancer therapeutics","volume":"7","author":"Khilwani","year":"2024","journal-title":"ACS Pharmacol Trans Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102706","article-title":"Systems biology and cytokines potential role in lung cancer immunotherapy targeting autophagic axis","volume":"11","author":"Khilwani","year":"2023","journal-title":"Biomedicines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12964-024-01504-1","article-title":"The interaction of inflammasomes and gut microbiota: novel therapeutic insights","volume":"22","author":"Manshouri","year":"2024","journal-title":"Cell communication signaling: CCS"},{"key":"B62","volume-title":"Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.","author":"De Luca","year":"2025"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e13452","DOI":"10.15252\/emmm.202013452","article-title":"Interaction between the inflammasome and commensal microorganisms in gastrointestinal health and disease","volume":"13","author":"Watanabe","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MR0720-472RR","article-title":"The role of the microbiome and the NLRP3 inflammasome in the gut and lung","volume":"108","author":"Donovan","year":"2020","journal-title":"J leukocyte Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41467-017-01917-2","article-title":"Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis","volume":"8","author":"Yao","year":"2017","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.03.004","article-title":"Distinct commensals induce interleukin-1\u03b2 via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury","volume":"42","author":"Seo","year":"2015","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal transduction targeted Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021216","article-title":"Traversing through the mechanistic event analysis in IL-6 and IL-17 signaling for a new therapeutic paradigm in NSCLC","volume":"25","author":"Khilwani","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.04.004","article-title":"Lung tumor immunity: redirecting macrophages through infection-induced inflammation","volume":"46","author":"Aktay-Cetin","year":"2025","journal-title":"Trends Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/s12276-024-01327-7","article-title":"Author Correction: STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation","volume":"56","author":"Luo","year":"2024","journal-title":"Exp Mol Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155742","article-title":"Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints","volume":"149","author":"Jarlborg","year":"2022","journal-title":"Cytokine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201836109","article-title":"NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis","volume":"109","author":"Inoue","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195572","article-title":"The roles of inflammasomes in cancer","volume":"14","author":"Deng","year":"2023","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"70","DOI":"10.37349\/ei.2023.00090","article-title":"Inflammasomes driven inflammation in lung cancer revisited: A short review","volume":"3","author":"da Costa","year":"2023","journal-title":"Explor Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1296295","article-title":"Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected","volume":"14","author":"Cheng","year":"2024","journal-title":"Front Cell infection Microbiol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2023.03.002","article-title":"Assembling symbiotic bacterial species into live therapeutic consortia that reconstitute microbiome functions","volume":"31","author":"Oliveira","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13442","article-title":"Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients","volume":"11","author":"Song","year":"2020","journal-title":"Thorac Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Sci (New York N.Y.)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3920\/BM2011.0005","article-title":"Bifidobacterium breve - HT-29 cell line interaction: modulation of TNF-\u03b1 induced gene expression","volume":"2","author":"Boesten","year":"2011","journal-title":"Beneficial Microbes"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115332","article-title":"Novel strategies for modulating the gut microbiome for cancer therapy","volume":"210","author":"Cho","year":"2024","journal-title":"Advanced Drug delivery Rev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goab046","article-title":"Microbiome therapeutics: exploring the present scenario and challenges","volume":"10","author":"Yadav","year":"2021","journal-title":"Gastroenterol Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2015.0134","article-title":"Lipopolysaccharide-mediated induction of concurrent IL-1\u03b2 and IL-23 expression in THP-1 cells exhibits differential requirements for caspase-1 and cathepsin B activity","volume":"36","author":"Wynick","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.172","article-title":"Engineering bacteria for diagnostic and therapeutic applications","volume":"16","author":"Riglar","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.11.002","article-title":"Synthetic biology tools to engineer microbial communities for biotechnology","volume":"37","author":"McCarty","year":"2019","journal-title":"Trends Biotechnol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00203-025-04417-w","article-title":"Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study","volume":"207","author":"Sadhu","year":"2025","journal-title":"Arch Microbiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e14001","DOI":"10.1111\/apha.14001","article-title":"Engineering bacteria to modulate host metabolism","volume":"238","author":"Ciocan","year":"2023","journal-title":"Acta physiologica (Oxford England)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040844","article-title":"Genome editing in bacteria: CRISPR-cas and beyond","volume":"9","author":"Arroyo-Olarte","year":"2021","journal-title":"Microorganisms"},{"key":"B89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12934-020-01318-z","article-title":"Engineering probiotics as living diagnostics and therapeutics for improving human health","volume":"19","author":"Zhou","year":"2020","journal-title":"Microbial Cell factories"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.2c00649","article-title":"CRISPR-cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance","volume":"9","author":"Mayorga-Ramos","year":"2023","journal-title":"ACS Infect Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211299","article-title":"Recent advances in genetic tools for engineering probiotic lactic acid bacteria","volume":"43","author":"Mugwanda","year":"2023","journal-title":"Bioscience Rep"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41467-021-21740-0","article-title":"Applications, challenges, and needs for employing synthetic biology beyond the lab","volume":"12","author":"Brooks","year":"2021","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1038\/s41467-020-20122-2","article-title":"Synthetic biology 2020-2030: six commercially-available products that are changing our world","volume":"11","author":"Voigt","year":"2020","journal-title":"Nat Commun"},{"key":"B94","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41392-023-01440-5","article-title":"Applications of synthetic biology in medical and pharmaceutical fields","volume":"8","author":"Yan","year":"2023","journal-title":"Signal transduction targeted Ther"},{"key":"B95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jobb.2018.12.003","article-title":"Synthetic biology: recent progress, biosafety and biosecurity concerns, and possible solutions","volume":"1","author":"Wang","year":"2019","journal-title":"J Biosafety Biosecur"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2021.100297","article-title":"Design patterns for engineering genetic stability","volume":"19","author":"Son","year":"2021","journal-title":"Curr\u00a0Opin Biomed Eng"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1511149","article-title":"Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine","volume":"12","author":"Nazir","year":"2024","journal-title":"Front bioengineering Biotechnol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1272788","article-title":"Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12032-024-02422-5","article-title":"Interleukin-6 serves as a critical factor in various cancer progression and therapy","volume":"41","author":"Mohamed","year":"2024","journal-title":"Med Oncol (Northwood London England)"},{"key":"B100","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat Commun"},{"key":"B101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479505","article-title":"The role of interleukin-17 in inflammation-related cancers","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4110\/in.2020.20.e6","article-title":"IL-17-producing cells in tumor immunity: friends or foes","volume":"20","author":"Kuen","year":"2020","journal-title":"Immune network"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177360","article-title":"Endogenous IL-17 contributes to reduced tumor growth and metastasis","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1619874","article-title":"Genetic improvement of a synthetic microbiota: a step further","volume":"16","author":"Mart\u00ednez-Porchas","year":"2025","journal-title":"Front Microbiol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2407.07004","article-title":"Synthetic biology-driven microbial therapeutics for disease treatment","volume":"34","author":"Kim","year":"2024","journal-title":"J Microbiol Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1649517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T05:11:37Z","timestamp":1764047497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1649517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":106,"alternative-id":["10.3389\/fimmu.2025.1649517"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1649517","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"1649517"}}